anti galectin 3 binding protein  (R&D Systems)

Journal: Cancer Science

Article Title: MZT2A promotes NSCLC viability and invasion by increasing Akt phosphorylation via the MOZART2 domain

doi: 10.1111/cas.14900

Figure Lengend Snippet: MZT2A‐activated Akt signal transduction via LGALS3BP. A, Co‐IP‐western blot. A549 and H1299 cells were grown and subjected to Co‐IP‐western blot analysis to detect the intact interaction between MZT2A and LGALS3BP proteins B, Immunohistochemistry and Pearson correlation analysis. NSCLC tissue sections were immunostained with an anti‐MZT2A or LGALS3BP antibody and the expression of MZT2A and LGALS3BP protein was scored as high or low. Tissue sections were subjected to Pearson correlation analysis (shown in the graph; P < .05). C, Western blot. A549 and H1299 cells were grown, transfected with MZT2A cDNA and/or LGALS3BP siRNA, and subjected to western blot analysis. D, Cell viability MTT assay. A549 and H1299 cells were grown, transfected with MZT2A cDNA and/or LGALS3BP siRNA, and subjected to MTT assays. E, Transwell assay. A549 and H1299 cells were grown, transfected with MZT2A cDNA and/or LGALS3BP siRNA, and subjected to Transwell assays. Graph shows the quantified data

Article Snippet: The sections were then incubated with an anti‐MZT2A antibody at a dilution of 1:200 (Thermo) or an anti‐galectin‐3‐binding protein (LGALS3BP) antibody at a dilution of 1:300 (Cat. 10281‐1‐AP; Proteintech) at 4°C overnight.

Techniques: Transduction, Co-Immunoprecipitation Assay, Western Blot, Immunohistochemistry, Expressing, Transfection, MTT Assay, Transwell Assay